|
1
|
Shi J, Qu YP and Hou P: Pathogenetic
mechanisms in gastric cancer. World J Gastroenterol.
20:13804–13819. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Piazuelo MB and Correa P: Gastric cancer:
Overview. Colomb Med (Cali). 44:192–201. 2013.PubMed/NCBI
|
|
3
|
Li Z, Lei H, Luo M, Wang Y, Dong L, Ma Y,
Liu C, Song W, Wang F, Zhang J, et al: DNA methylation
downregulated mir-10b acts as a tumor suppressor in gastric cancer.
Gastric Cancer. 18:43–54. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Qiu T, Zhou X, Wang J, Du Y, Xu J, Huang
Z, Zhu W, Shu Y and Liu P: MiR-145, miR-133a and miR-133b inhibit
proliferation, migration, invasion and cell cycle progression via
targeting transcription factor Sp1 in gastric cancer. FEBS Lett.
588:1168–1177. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ford CE, Ma SS Qian, Quadir A and Ward RL:
The dual role of the novel Wnt receptor tyrosine kinase, ROR2, in
human carcinogenesis. Int J Cancer. 133:779–787. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sundaram MV: Canonical RTK-Ras-ERK
signaling and related alternative pathways. WormBook. 1–38. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jimenez G, Shvartsman SY and Paroush Z:
The Capicua repressor-a general sensor of RTK signaling in
development and disease. J Cell Sci. 125:1383–1391. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Batchu SN and Korshunov VA: Novel tyrosine
kinase signaling pathways: Implications in vascular remodeling.
Curr Opin Nephrol Hypertens. 21:122–127. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Enomoto M, Hayakawa S, Itsukushima S, Ren
DY, Matsuo M, Tamada K, Oneyama C, Okada M, Takumi T, Nishita M and
Minami Y: Autonomous regulation of osteosarcoma cell invasiveness
by Wnt5a/Ror2 signaling. Oncogene. 28:3197–3208. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li L, Ying J, Tong X, Zhong L, Su X, Xiang
T, Shu X, Rong R, Xiong L, Li H, et al: Epigenetic identification
of receptor tyrosine kinase-like orphan receptor 2 as a functional
tumor suppressor inhibiting β-catenin and AKT signaling but
frequently methylated in common carcinomas. Cell Mol Life Sci.
71:2179–2192. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lu BJ, Wang YQ, Wei XJ, Rong LQ, Wei D,
Yan CM, Wang DJ and Sun JY: Expression of WNT-5a and ROR2
correlates with disease severity in osteosarcoma. Mol Med Rep.
5:1033–1036. 2012.PubMed/NCBI
|
|
12
|
Wright TM, Brannon AR, Gordan JD, Mikels
AJ, Mitchell C, Chen S, Espinosa I, van de Rijn M, Pruthi R, Wallen
E, et al: Ror2, a developmentally regulated kinase, promotes tumor
growth potential in renal cell carcinoma. Oncogene. 28:2513–2523.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Katoh M: WNT signaling pathway and stem
cell signaling network. Clin Cancer Res. 13:4042–4045. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
O'Connell MP, Fiori JL, Xu M, Carter AD,
Frank BP, Camilli TC, French AD, Dissanayake SK, Indig FE, Bernier
M, et al: The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A
signaling in metastatic melanoma. Oncogene. 29:34–44. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Green J, Nusse R and van Amerongen R: The
role of Ryk and Ror receptor tyrosine kinases in Wnt signal
transduction. Cold Spring Harb Perspect Biol. 6:2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Heo SH, Jeong ES, Lee KS, Seo JH, Jeong
DG, Won YS, Kwon HJ, Kim HC, Kim DY and Choi YK: Canonical Wnt
signaling pathway plays an essential role in N-methyl-N-nitrosurea
induced gastric tumorigenesis of mice. J Vet Med Sci. 75:299–307.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Stricker S and Mundlos S: FGF and ROR2
receptor tyrosine kinase signaling in human skeletal development.
Curr Top Dev Biol. 97:179–206. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kobayashi M, Shibuya Y, Takeuchi J, Murata
M, Suzuki H, Yokoo S, Umeda M, Minami Y and Komori T: Ror2
expression in squamous cell carcinoma and epithelial dysplasia of
the oral cavity. Oral Surg Oral Med Oral Pathol Oral Radiol Endod.
107:398–406. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lerner UH and Ohlsson C: The WNT system:
Background and its role in bone. J Intern Med. 277:630–649. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jones AE, Price FD, Le Grand F, Soleimani
VD, Dick SA, Megeney LA and Rudnicki MA: Wnt/β-catenin controls
follistatin signalling to regulate satellite cell myogenic
potential. Skelet Muscle. 5:142015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
He H, Chen K, Wang F, Zhao L, Wan X, Wang
L and Mo Z: miR204-5p promotes the adipogenic differentiation of
human adipose-derived mesenchymal stem cells by modulating DVL3
expression and suppressing Wnt/beta-catenin signaling. Int J Mol
Med. 35:1587–1595. 2015.PubMed/NCBI
|
|
23
|
Chang B, Tessneer KL, McManus J, Liu X,
Hahn S, Pasula S, Wu H, Song H, Chen Y, Cai X, et al: Epsin is
required for dishevelled stability and Wnt signalling activation in
colon cancer development. Nat Commun. 6:63802015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xie J, Zhang Y, Hu X, Lv R, Xiao D, Jiang
L and Bao Q: Norcantharidin inhibits Wnt signal pathway via
promoter demethylation of WIF-1 in human non-small cell lung
cancer. Med Oncol. 32:1452015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ashihara E, Takada T and Maekawa T:
Targeting the canonical Wnt/β-catenin pathway in hematological
malignancies. Cancer Sci. 106:665–671. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ilmer M, Boiles AR, Regel I, Yokoi K,
Michalski CW, Wistuba II, Rodriguez J, Alt E and Vykoukal J: RSPO2
enhances canonical wnt signaling to confer stemness-associated
traits to susceptible pancreatic cancer cells. Cancer Res.
75:1883–1896. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fang F, Zhao WY, Li RK, Yang XM, Li J, Ao
JP, Jiang SH, Kong FZ, Tu L, Zhuang C, et al: Silencing of WISP3
suppresses gastric cancer cell proliferation and metastasis and
inhibits Wnt/β-catenin signaling. Int J Clin Exp Pathol.
7:6447–6461. 2014.PubMed/NCBI
|
|
28
|
Geng M, Cao YC, Chen YJ, Jiang H, Bi LQ
and Liu XH: Loss of Wnt5a and Ror2 protein in hepatocellular
carcinoma associated with poor prognosis. World J Gastroenterol.
18:1328–1338. 2012. View Article : Google Scholar : PubMed/NCBI
|
